Bet_Noire/iStock via Getty Images GoodRx ( NASDAQ: GDRX ) and Boehringer Ingelheim on Thursday announced an initiative to launch the German drugmaker’s biosimilar against AbbVie’s ( NYSE: ABBV ) Humira (adalimumab) at an exclusively low cash price in the U.S. From July 18, Boehringer’s interchangeable biosimilar targeting Humira will be available for $550 per two-pack as a pre-filled syringe or autoinjector across more than 70,000 pharmacies nationwide, the companies said.
Its price implies an over 92% discount from the reference product’s list price. AbbVie’s ( ABBV ) blockbuster arthritis therapy went off patent last year, paving the way for biosimilars, including Boehringer’s unbranded and branded versions launched in 2023 at an 81% and 5% discount to the reference product, respectively. “This program is a significant step in addressing access and affordability in one of the largest therapeutic categories with a high cost burden for patients,” GoodRx ( GDRX ) and Boehringer said.
More on GoodRx Holdings GoodRx: Encouraging Profit Stabilization (Rating Upgrade) GoodRx Holdings, Inc. (GDRX) Q1 2024 Earnings Call Transcript RBC Capital raises GoodRx to outperform, cites growth opportunities GoodRx rallies for second day amid Kroger deal, analyst upgrade Seeking Alpha’s Quant Rating on GoodRx Holdings.
